Agenus shared on LinkedIn:
“Bold Science. Big Questions. A Defining Moment for Cancer Immunotherapy.
On Saturday, October 24, at 6:15 PM in Madrid, Jennifer S. Buell joins global oncology leaders, including Prof. Jean-Yves Blay, Dr. Julie Gralow, and Martha Raymond for OncoDaily’s Big Questions discussion.
The science is advancing. The urgency is real. Some countries are already acting. How quickly can we bring promising breakthroughs to patients around the world?
ESMO 2026 | October 24 | 6:15 PM | Madrid.”
Garo Armen, Chairman and CEO at Agenus, added:
“Our Agenus presence at ESMO26 – with three BOT+BAL data updates, advance of the ROBBIN Trial, OncoDaily Grand Rounds in Sarcoma, and Jennifer S. Buell joining global oncology leaders on accelerating patient access – underscores our mission to advance the science, challenge conventional timelines, and accelerate patient access worldwide.”
Event Highlights
- The Fragility of Clinical Evidence: When a promising trial collapses prematurely, the damage extends far beyond lost funding. We explore why critical studies fail to reach the finish line, how to salvage value from aborted trials, and what happens to the patients and investigators left in the wake.
- Redefining Approval Thresholds: Accelerated pathways, surrogate endpoints, and single-arm data have changed how drugs reach the market. But how much uncertainty is acceptable? The panel unpacks how regulators balance speed against safety, and how post-market evidence must evolve to fill the gaps.
- The Regulatory vs. Clinical Divide: A dataset that satisfies a regulatory agency doesn’t always convince a practicing oncologist – or vice versa. We examine why different stakeholders draw contrasting conclusions from the exact same trial data, and how early cross-sector dialogue can align development with real-world care.
- Closing the “Approved vs. Available” Gap: Securing regulatory clearance is only half the battle. Reassessing health economics, regional reimbursement delays, and hospital formulary hurdles reveals why an effective treatment on paper remains out of reach at the bedside – and who must step up to fix it.
Learn more and register for the Big Questions During ESMO 2026.
You may also be interested in: Only a Few Days Until OncoDaily Grand Rounds at ESMO 2026: Sarcoma Edition
